Kyverna director receives RSUs and stock options
Kyverna Therapeutics director Ian T. Clark received new equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Kyverna Therapeutics director Ian T. Clark received new equity awards. He was granted 5,093 restricted stock units of common stock, bringing his direct common share holdings to 21,727. He also received options for 20,582 shares at an exercise price of $8.59, expiring in 2036.
Both the RSUs and options will fully vest on the earlier of May 27, 2027, or immediately before Kyverna’s 2027 annual stockholders’ meeting, as long as he remains in continuous service through that date.
Insider Trade Summary
Grant/Award: 25,675 shares
Grant/Award
2 txns
Insider
CLARK IAN T
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 20,582 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 5,093 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 20,582 contracts (Direct);
Common Stock — 21,727 shares (Direct)
Footnotes (2)
- F1. Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
- F2. All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Key Figures
RSU grant: 5,093 shares
Common shares after grant: 21,727 shares
Option grant size: 20,582 shares
+2 more
5 metrics
RSU grant
5,093 shares
Restricted stock unit award of common stock
Common shares after grant
21,727 shares
Direct common stock holdings after RSU award
Option grant size
20,582 shares
Stock Option (right to buy) underlying common shares
Option exercise price
$8.59 per share
Conversion or exercise price for stock option grant
Option expiration
2036-05-27
Expiration date of the stock option grant
Key Terms
restricted stock unit, Stock Option (right to buy), vest, annual meeting of stockholders
4 terms
restricted stock unit financial
"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (right to buy) financial
"Stock Option (right to buy) with underlying security title Common Stock and 20,582.0000 shares"
vest financial
"which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting of stockholders financial
"immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Kyverna Therapeutics (KYTX) report for Ian T. Clark?
Kyverna Therapeutics reported that director Ian T. Clark received equity compensation, including restricted stock units and stock options. These awards increase his direct ownership stake and align his interests with shareholders through time-based vesting tied to his continued service on the board.
What are the details of Ian T. Clark’s Kyverna Therapeutics (KYTX) stock option grant?
Clark received stock options covering 20,582 Kyverna common shares at an exercise price of $8.59 per share. All option shares will become fully vested and exercisable in 2027, provided he maintains continuous service, and the options are scheduled to expire in 2036 if not exercised earlier.
When do Ian T. Clark’s new Kyverna Therapeutics (KYTX) equity awards vest?
Both the restricted stock units and the stock options will fully vest on the earlier of May 27, 2027, or immediately before Kyverna’s 2027 annual stockholders’ meeting. Vesting depends on Clark’s continuous service with the company through the applicable vesting date, without interruption.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates